On Dec. 14, 2021, NRx Pharmaceuticals provided a new safety update on ZYESAMIﾮ (aviptadil), which was being tested in the ACTIV-3b Critical Care Phase 3 study sponsored by the US National Institutes of Health.

In its third scheduled analysis, the studyﾒs Independent Data Safety Monitoring Board found no new safety concerns after reviewing a total of 348 patients and recommended continued enrollment.